arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Larimar Therapeutics, Inc.

LRMR
$2.30 ▼ -0.47 (-16.82%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
56 Visible periods
23 Metrics
Peer-ranked Benchmarks
Price Chart
15
Health
Poor
Bearish
auto_awesome

Analytical Summary

Larimar Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -21.3% ↘
FCF / Share None
Trailing P/E —
Price / Book 1.9x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

56-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-29.61M
↓ -1.1% —
FCF / Share Free cash flow per share
$-0.42
↓ -113.8% —
Long-Term Debt Long-term obligations
$16.36M
↓ -10.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
2
Cash Quality ↓
48

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 15 years · 56 quarters